Ligand associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3 dependent cancer cells

Somatic alterations of Fibroblast Growth Factor Receptors (FGFRs) have been described in a wide range of malignancies. A number of anti-FGFR therapies are currently under investigation in clinical trials for subjects with FGFR gene amplifications, mutations and translocations. Here, we develop cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun, Mikse, Oliver, Liao, Rachel G., Li, Yvonne, Tan, Li, Janne, Pasi A., Gray, Nathanael S., Wong, Kwok-kin, Hammerman, Peter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261066/
https://www.ncbi.nlm.nih.gov/pubmed/24909170
http://dx.doi.org/10.1038/onc.2014.161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261066/
https://www.ncbi.nlm.nih.gov/pubmed/24909170
http://dx.doi.org/10.1038/onc.2014.161

Ejemplares similares